Skip to main content
Top
Published in: Acta Diabetologica 3/2019

01-03-2019 | Original Article

Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L

Authors: Mitsuyoshi Takahara, Naoto Katakami, Toshihiko Shiraiwa, Katsushige Abe, Hideo Ayame, Yasuaki Ishimaru, Masahiro Iwamoto, Mitsuo Shimizu, Osamu Tomonaga, Hiroki Yokoyama, Taka-aki Matsuoka, Iichiro Shimomura

Published in: Acta Diabetologica | Issue 3/2019

Login to get access

Abstract

Aims

This study aimed to reveal health utility values for diabetic complications and treatment regimens with adjustment for glycemic control and other clinical manifestations in a diabetic population.

Methods

The EuroQol 5-Dimension 5-Level (EQ-5D-5L) health utility values for 4963 Japanese diabetic patients were analyzed using a multivariate regression model including major complications and treatment regiments (minimally adjusted model), and that additionally included glycemic control and other subjective symptoms (musculoskeletal, dental, respiratory, gastrointestinal, urinary, and cutaneous symptoms, and hearing impairment) (further adjusted model).

Results

The mean utility value was 0.901 ± 0.137. In the minimally adjusted model, blindness, overt nephropathy, regular dialysis, cardiac symptom, sequelae of stroke, symptomatic peripheral neuropathy, decreased sensation, claudication, foot ulcer/gangrene, major amputation, and complex treatment regimens were significantly associated with lower utility values, whereas proliferative retinopathy without blindness, coronary artery disease without cardiac symptom, sequela-free cerebrovascular disease, asymptomatic peripheral artery disease, and minor amputation were not. Major complications and treatment regimens that showed significant association in the minimally adjusted model still presented significant impact on the utility decrement in the further adjusted model. However, most of their regression coefficients were lower in absolute value compared to those in the minimally adjusted model.

Conclusions

The utility decrement related to each diabetic complication varied with its severity and accompanying symptoms. Complex treatment regimens were independently associated with lower utility values. The utility decrement associated with diabetic complication and complex treatment regimens would be overestimated in the analysis without adjustment for glycemic control or other subjective symptoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Narayan KM, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F (2000) Diabetes–a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 50(Suppl 2):S77–S84CrossRefPubMed Narayan KM, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F (2000) Diabetes–a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 50(Suppl 2):S77–S84CrossRefPubMed
2.
go back to reference Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253–1258CrossRefPubMed Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253–1258CrossRefPubMed
3.
go back to reference Richardson G, Manca A (2004) Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ 13:1203–1210CrossRefPubMed Richardson G, Manca A (2004) Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ 13:1203–1210CrossRefPubMed
5.
go back to reference Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed
6.
go back to reference Bagust A, Beale S (2005) Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 14:217–230CrossRefPubMed Bagust A, Beale S (2005) Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 14:217–230CrossRefPubMed
7.
go back to reference Zhang P, Brown MB, Bilik D, Ackermann RT, Li R, Herman WH (2012) Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care 35:2250–2256CrossRefPubMedPubMedCentral Zhang P, Brown MB, Bilik D, Ackermann RT, Li R, Herman WH (2012) Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care 35:2250–2256CrossRefPubMedPubMedCentral
8.
go back to reference Kiadaliri AA, Gerdtham UG, Eliasson B, Gudbjornsdottir S, Svensson AM, Carlsson KS (2014) Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health 11:4939–4952CrossRefPubMedPubMedCentral Kiadaliri AA, Gerdtham UG, Eliasson B, Gudbjornsdottir S, Svensson AM, Carlsson KS (2014) Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health 11:4939–4952CrossRefPubMedPubMedCentral
9.
go back to reference Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J (2016) The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making 36:1020–1033CrossRefPubMedPubMedCentral Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J (2016) The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making 36:1020–1033CrossRefPubMedPubMedCentral
10.
go back to reference Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26:1553–1579CrossRefPubMed Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26:1553–1579CrossRefPubMed
11.
go back to reference Casanova L, Hughes FJ, Preshaw PM (2014) Diabetes and periodontal disease: a two-way relationship. Br Dent J 217:433–437CrossRefPubMed Casanova L, Hughes FJ, Preshaw PM (2014) Diabetes and periodontal disease: a two-way relationship. Br Dent J 217:433–437CrossRefPubMed
12.
go back to reference Petrou S, Hockley C (2005) An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 14:1169–1189CrossRefPubMed Petrou S, Hockley C (2005) An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ 14:1169–1189CrossRefPubMed
13.
go back to reference Bharmal M, Thomas J (2006) Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9:262–271CrossRefPubMed Bharmal M, Thomas J (2006) Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9:262–271CrossRefPubMed
14.
go back to reference Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884CrossRefPubMed Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13:873–884CrossRefPubMed
15.
go back to reference Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRefPubMedPubMedCentral Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736CrossRefPubMedPubMedCentral
16.
go back to reference Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA (2014) Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes 12:74CrossRefPubMedPubMedCentral Agborsangaya CB, Lahtinen M, Cooke T, Johnson JA (2014) Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health Qual Life Outcomes 12:74CrossRefPubMedPubMedCentral
17.
go back to reference Wang P, Luo N, Tai ES, Thumboo J (2016) The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore. Value Health Reg Issues 9:57–62CrossRefPubMed Wang P, Luo N, Tai ES, Thumboo J (2016) The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore. Value Health Reg Issues 9:57–62CrossRefPubMed
18.
go back to reference Ikeda S, Shiroiwa T, Igarashi A et al (2015) Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health 64:47–55 Ikeda S, Shiroiwa T, Igarashi A et al (2015) Developing a Japanese version of the EQ-5D-5L value set. J Natl Inst Public Health 64:47–55
20.
go back to reference Pullenayegum EM, Tarride JE, Xie F, Goeree R, Gerstein HC, O’Reilly D (2010) Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health 13:487–494CrossRefPubMed Pullenayegum EM, Tarride JE, Xie F, Goeree R, Gerstein HC, O’Reilly D (2010) Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health 13:487–494CrossRefPubMed
21.
go back to reference Laxy M, Wilson ECF, Boothby CE, Griffin SJ (2017) Incremental costs and cost effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: an update with empirical trial-based cost data. Value Health 20:1288–1298CrossRefPubMedPubMedCentral Laxy M, Wilson ECF, Boothby CE, Griffin SJ (2017) Incremental costs and cost effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: an update with empirical trial-based cost data. Value Health 20:1288–1298CrossRefPubMedPubMedCentral
22.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed
23.
go back to reference Vijan S, Sussman JB, Yudkin JS, Hayward RA (2014) Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174:1227–1234CrossRefPubMedPubMedCentral Vijan S, Sussman JB, Yudkin JS, Hayward RA (2014) Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 174:1227–1234CrossRefPubMedPubMedCentral
24.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMedPubMedCentral Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMedPubMedCentral
25.
go back to reference Ikeda Y, Kubo T, Oda E, Abe M, Tokita S (2018) Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: retrospective diagnosis procedure combination database analysis. J Diabetes Investig 9:925–936CrossRefPubMedPubMedCentral Ikeda Y, Kubo T, Oda E, Abe M, Tokita S (2018) Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: retrospective diagnosis procedure combination database analysis. J Diabetes Investig 9:925–936CrossRefPubMedPubMedCentral
26.
go back to reference Shim YT, Lee J, Toh MP, Tang WE, Ko Y (2012) Health-related quality of life and glycaemic control in patients with Type 2 diabetes mellitus in Singapore. Diabet Med 29:e241–e248CrossRefPubMed Shim YT, Lee J, Toh MP, Tang WE, Ko Y (2012) Health-related quality of life and glycaemic control in patients with Type 2 diabetes mellitus in Singapore. Diabet Med 29:e241–e248CrossRefPubMed
27.
go back to reference Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P (2006) Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 22:1523–1534CrossRefPubMed Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P (2006) Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 22:1523–1534CrossRefPubMed
28.
go back to reference Southerland JH, Moss K, Taylor GW et al (2012) Periodontitis and diabetes associations with measures of atherosclerosis and CHD. Atherosclerosis 222:196–201CrossRefPubMed Southerland JH, Moss K, Taylor GW et al (2012) Periodontitis and diabetes associations with measures of atherosclerosis and CHD. Atherosclerosis 222:196–201CrossRefPubMed
29.
go back to reference Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161:1989–1996CrossRefPubMed Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161:1989–1996CrossRefPubMed
30.
go back to reference Frimodt-Moller C (1980) Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 92:318–321CrossRefPubMed Frimodt-Moller C (1980) Diabetic cystopathy: epidemiology and related disorders. Ann Intern Med 92:318–321CrossRefPubMed
32.
go back to reference Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M (1981) Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 305:191–194CrossRefPubMed Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M (1981) Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 305:191–194CrossRefPubMed
34.
go back to reference Blagojevic M, Jinks C, Jeffery A, Jordan KP (2010) Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthr Cartil 18:24–33CrossRef Blagojevic M, Jinks C, Jeffery A, Jordan KP (2010) Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthr Cartil 18:24–33CrossRef
35.
go back to reference Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ (2016) Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009 to 2011. J Diabetes Complicat 30:212–220CrossRef Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ (2016) Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009 to 2011. J Diabetes Complicat 30:212–220CrossRef
36.
go back to reference Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31:2038–2043CrossRefPubMedPubMedCentral Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31:2038–2043CrossRefPubMedPubMedCentral
38.
go back to reference Bainbridge KE, Hoffman HJ, Cowie CC (2008) Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 149:1–10CrossRefPubMedPubMedCentral Bainbridge KE, Hoffman HJ, Cowie CC (2008) Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 149:1–10CrossRefPubMedPubMedCentral
39.
go back to reference Bainbridge KE, Hoffman HJ, Cowie CC (2011) Risk factors for hearing impairment among U.S. adults with diabetes: National Health and Nutrition Examination Survey 1999–2004. Diabetes Care 34:1540–1545CrossRefPubMedPubMedCentral Bainbridge KE, Hoffman HJ, Cowie CC (2011) Risk factors for hearing impairment among U.S. adults with diabetes: National Health and Nutrition Examination Survey 1999–2004. Diabetes Care 34:1540–1545CrossRefPubMedPubMedCentral
40.
go back to reference Bradshaw PJ, Jamrozik KD, Gilfillan IS, Thompson PL (2006) Asymptomatic long-term survivors of coronary artery bypass surgery enjoy a quality of life equal to the general population. Am Heart J 151:537–544CrossRefPubMed Bradshaw PJ, Jamrozik KD, Gilfillan IS, Thompson PL (2006) Asymptomatic long-term survivors of coronary artery bypass surgery enjoy a quality of life equal to the general population. Am Heart J 151:537–544CrossRefPubMed
42.
go back to reference Ragnarson Tennvall G, Apelqvist J (2000) Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complicat 14:235–241CrossRef Ragnarson Tennvall G, Apelqvist J (2000) Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complicat 14:235–241CrossRef
43.
go back to reference Rutherford RB, Baker JD, Ernst C et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517–538CrossRefPubMed Rutherford RB, Baker JD, Ernst C et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517–538CrossRefPubMed
44.
go back to reference Jia H, Lubetkin EI (2005) The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 27:156–164CrossRef Jia H, Lubetkin EI (2005) The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf) 27:156–164CrossRef
45.
go back to reference Busutil R, Espallardo O, Torres A, Martinez-Galdeano L, Zozaya N, Hidalgo-Vega A (2017) The impact of obesity on health-related quality of life in Spain. Health Qual Life Outcomes 15:197CrossRefPubMedPubMedCentral Busutil R, Espallardo O, Torres A, Martinez-Galdeano L, Zozaya N, Hidalgo-Vega A (2017) The impact of obesity on health-related quality of life in Spain. Health Qual Life Outcomes 15:197CrossRefPubMedPubMedCentral
Metadata
Title
Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L
Authors
Mitsuyoshi Takahara
Naoto Katakami
Toshihiko Shiraiwa
Katsushige Abe
Hideo Ayame
Yasuaki Ishimaru
Masahiro Iwamoto
Mitsuo Shimizu
Osamu Tomonaga
Hiroki Yokoyama
Taka-aki Matsuoka
Iichiro Shimomura
Publication date
01-03-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1244-6

Other articles of this Issue 3/2019

Acta Diabetologica 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine